

Q1 2018 RESULTS



NET COMPANY SALES & BUSINESS EPS

€7,898M


Q1 2018 SALES

€1.28 Q1 2018 BUSINESS EPS

NET SALES BY GLOBAL BUSINESS UNIT

	GENERAL MEDICINES & EMERGING MARKETS	€3,401M
	SANOFI GENZYME (SPECIALTY CARE)	€1,460M
	CONSUMER HEALTHCARE	€1,238M
	DIABETES & CARDIOVASCULAR	€1,088M
	SANOFI PASTEUR (VACCINES)	€711M

SALES BY GEOGRAPHY



*Note that image is illustrative only. Rest of the World: Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico. Eurasia: Russia, Ukraine, Georgia, Belarus, Armenia and Turkey

R&D HIGHLIGHTS

74

projects in development for NMEs or additional indications

28

projects in advanced clinical trial